Explore ›
Finding
Finding
null
There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.
| Comparator | 1 cycle of bridging chemotherapy prior to CD19-specific CAR T cell infusion |
| Effect summary | null |
Connected entities
Interventions
Outcomes
Source
PMC9361393
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia